Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Definitions

• the present invention relates to a novel pharmaceutical composition
• a novel pharmaceutical composition comprising dabigatran etexilate free base as an active agent and at least one pharmaceutically acceptable excipient.
• WO2012/077136 is directed to the oxalate salt of dabigatran etexilate and besides, its hydrochloride salt is identified in EP1877395 .
• An active agent should meet some physicochemical requirements in order to be capable of being used in pharmaceutical compositions. These requirements considerably depend on the physicochemical properties of the active agent used in pharmaceutical composition.
• dabigatran etexilate salts disclosed in prior art, were compared for their physicochemical properties like water solubility, stability, impurity non-hygroscopicity and processability which are important for the development of pharmaceutical compositions.
• a pharmaceutical composition comprising a stable, pure, soluble, non-hygroscopic and processable form of dabigatran etexilate.
• Another object of the present invention is to provide a stable pharmaceutical composition comprising dabigatran etexilate free base with a reduced moisture content, wherein the content of dabigatran etexilate free base is correctly adjusted by minimizing the absorption of moisture.
• the present invention is directed to novel pharmaceutical composition
• novel pharmaceutical composition comprising dabigatran etexilate free base as active agent and at least one pharmaceutically acceptable excipient.
• dabigatran etexilate free base refers to dabigatran etexilate which is free from other forms of the active moiety, especially acid addition salts.
• said pharmaceutical composition contains dabigatran etexilate free base having an impurity not more than 1%, preferably not more than 0.7% and more preferably not more than 0.4% of the dabigatran etexilate free base content.
• the impurity of dabigatran etexilate free base may be determined by any methos known in the art, including, but not limited to high performance liquid chromatography (HPLC) analysis.
• said pharmaceutical composition contains dabigatran etexilate free base wherein the moisture content of dabigatran etexilate free base is not more than 1% and preferably not more than 0.5% of dabigatran etexilate free base content.
• said pharmaceutical composition contains dabigatran etexilate free base having,
• said pharmaceutical composition contains dabigatran etexilate free base present in an amount from about 5 mg to about 300 mg, and preferably from about 25 mg to about 150 mg.
• dabigatran etexilate free base may be present in an amount between 5% and 75% by weight of the total composition.
• said pharmaceutical composition of dabigatran etexilate free base may be used for oral, parenteral, intranasal, sublingual, transdermal, transmucosal, ophtalmic, intravenous, pulmonary, intramuscular or rectal administration, and preferably for oral administration.
• said pharmaceutical composition may be formulated as tablets, buccal tablets, sublingual tablets, effervescent tablets, immediate release tablets, modified release tablets, film-coated tablets, orally disintegrating tablets, pills, capsules, caplets, powders, mini tablets, pellets, coated bead systems, granules, microspheres, ion exchange resin systems, steril ocular solutions, aerosols, sprays, drops, ampoules, suppusitories, ocular systems, parenteral systems, creams, gels, ointments, dragees, solutions, elixirs, suspensions or emulsions.
• said composition of dabigatran etexilate free base may comprise one or more pharmaceutically acceptable excipients selected from the group comprising stabilizers, buffering agent, disintegrants, diluents, dispersing agents, binders, lubricants, glidants, plasticizers, preservatives, sweeteners, controlled release agents, flavorings and coloring agents.
• Suitable stabilizers may include but not limited to citric acid, fumaric acid, tartaric acid, sodium citrate, sodium benzoate, sodium dihydrogen phosphate, calcium carbonate, magnesium carbonate, arginine, lysine, meglamine, tocopherol, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT), ascorbic acid, gallic acid esters and the mixtures thereof, and preferably, citric acid, fumaric acid, arginine ant mixtures thereof.
• said pharmaceutical composition comprises dabigatran etexilate free base as an active agent and at least one stabilizer as a pharmaceutically acceptable excipient.
• the combination of dabigatran etexilate free base and stabilizer in a unit dosage enhances stability parameter of the dosage form.
• Suitable buffering agent may include but not limited to alkali metal citrate, citric acid/sodium citrate, tartaric acid, fumaric acid, sorbic acid, citric acid, succinic acid, adipic acid, ascorbic acid, glutaric acid, potassium hydrogen tartrate, sodium hydrogen tartrate, potassium hydrogen phthalate, sodium hydrogen phthalate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, hydrochloric acid/sodium hydroxide and mixtures thereof, and preferably citric acid, fumaric acid, ascorbic acid, sodium dihydrogen phosphate and mixtures thereof.
• said pharmaceutical composition comprises i) dabigatran etexilate free base as an active agent, ii) at least one stabilizer, and iii) at least one buffering agent.
• buffering agent to adjust pH, provide optimum stability in the pharmaceutical composition of the present invention. Buffering agent minimizes changes in pH of the pharmaceutical composition and provides better solubility and stability of dabigatran etexilate free base which has a solubility strongly dependent to pH.
• said pharmaceutical composition contains
• said pharmaceutical composition contains
• Suitable disintegrants may include but not limited to cross-linked polyvinil pyrrolidone (crospovidone), povidone, cross-linked carboxymethyl cellulose (croscarmellose sodium), low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, sodium starch glycolate, alginic acid, alginates, ion-exchange resins, magnesium aluminium silica, sodium dodesyl sulphate, poloxamer, sodium glycine carbonate, sodium lauryl sulphate and mixtures thereof.
• cross-linked polyvinil pyrrolidone crospovidone
• povidone cross-linked carboxymethyl cellulose
• croscarmellose sodium cross-linked carboxymethyl cellulose
• Suitable diluents may include but not limited to microcrystalline cellulose, mannitol, spray-dried mannitol, lactose, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate and mixtures thereof.
• Suitable dispersing agents may include but not limited to calcium silicate, magnesium aluminum silicate and mixtures thereof.
• Suitable binders may include but not limited to polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, starch, pregelatinized starch, glucose, glucose syrup, natural gums, sucrose, sodium alginate, cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, gelatin, carrageenan, guar gum, carbomer, polymethacrylates, methacrylate polymers, collagens, proteins like gelatin, agar, alginate, xanthan gum, hyaluronic acid, pectin, polysaccharides, carbomer, poloxamer, polyacrylamide, aluminium hydroxide, laponit, bentonit, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide and mixtures thereof.
• Suitable lubricants may include but not limited to magnesium stearate, calcium stearate, zinc stearate, talc, waxes, boric acid, hydrogenated vegetable oil, sodium chlorate, magnesium lauryl sulfate, sodium oleate, sodium acetate, sodium benzoate, polyethylene glycol, stearic acid, fatty acid, fumaric acid, glyseryl palmito sulphate, sodium stearyl fumarate, sodium lauryl sulphate and mixtures thereof.
• Suitable preservatives may comprise but not limited to methyl paraben and propyl paraben and their salts (such as sodium, potassium), sodium benzoate, citric acid, benzoic acid, butylated hydroxytoluene and butylated hydroxyanisole and mixtures thereof.
• Suitable sweeteners may include but not limited to aspartame, potassium acesulfame, sodium saccharinate, neohesperidine dihydrochalcone, sucralose, saccharin, sugars such as sucrose, glucose, lactose, fructose and sugar alcohols such as mannitol, sorbitol, xylitol, erythritol and mixtures thereof.
• Suitable flavorings may include but not limited to menthol, peppermint, cinnamon, chocolate, vanillin and fruit essences such as cherry, orange, strawberry, grape, black currant, raspberry, banana, red fruits, wild berries etc. and mixtures thereof.
• said pharmaceutical composition may be formulated as a modified release dosage form comprising at least one controlled release agent as a pharmaceutically acceptable excipient.
• Said modified release dosage form can be a tablet, capsule, pellets, pellets in capsule, pellets in tablet, mini tablets, suspensions, powders, granules, sachet, caplet or pills.
• compositions of the present invention may be prepared by conventional technology well known to those skilled in the art such as direct compression, dry granulation, wet granulation and the like.
• direct compression active agent and excipients are mixed, sieved and compressed into dosage forms.
• wet granulation the ingredients are mixed and granulated with a granulation liquid. The granulation process provides agglomerates with a desired homogeneity. The mixture is sieved and optionally mixed with additional excipients. Finally, it is compressed into dosage forms.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=48093071

Family Applications (1)

Country Status (2)

Cited By (5)

Families Citing this family (1)

Citations (11)

• 2013
  • 2013-10-17 EP EP13189159.0A patent/EP2722033A1/fr not_active Withdrawn
  • 2013-10-17 WO PCT/EP2013/071776 patent/WO2014060545A1/fr not_active Ceased

Patent Citations (11)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events